2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1283

Utility of FDG-PET Imaging and Serological Biomarkers for Diagnosing Lymphadenopathy of IgG4-Related Diseas

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1464

Utility of Relative Cardiovascular Risk Score Scales and Vascular Age Predictors in Patients with Reumathoid Arthritis UNDER 50 YEARS of Age

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1465

Utility of Relative Cardiovascular Risk Score Scales in Patients UNDER the Age of 50 and Its Association with the Presence of Carotid Atherosclerosis in the Ultrasound

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1287

Utility of Vascular Findings By PET/CT Scan in the Diagnosis and Activity Assesment of Takayasu Arteritis

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1502

Vaccination Program to Prevent Hospital Admissions Due to Serious Respiratory Infections in Rheumatoid Arthritis Patients. Prosprective Study of 294 Patients

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1425

Validation of a Patient Reported Experience Measure (PREM) in Patients with Axial Spondyloarthropathies (AxSpA)

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1692

Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1665

Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

9:00AM-11:00AM: Abstract Number: 1420

Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1412

Validation of the Danish Version of the Stanford Health Assessment Questionnaire Disability Index and Determination of the Minimal Clinically Important Difference in a Cohort of Rheumatoid Arthritis Patients Using the Rasch Measurement Model

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1419

Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1697

Validity of Diagnostic Codes and Point Prevalence of Psoriatic Arthritis in Israel – a Population-Based Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1243

Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1793

Visceral Adiposity Assessed By DXA in Juvenile-Onset Systemic Lupus Erythematosus: A Correlation with Damage Index and Disease Duration

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1920

Vitamin D Induces a Type 1 Regulatory T Cell (Tr1)-like Phenotype in Human C-C Chemokine Receptor Type 6 (Ccr6)+ th Cells and Promotes Their Migration to an Inflammatory Environment

T Cell Biology and Targets in Autoimmune Disease - Poster Session I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].